Byra Reddy, MD
Allergy · Saint Joseph, MINPI 1487628483
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 559 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,814, 2.1 times the $859 reported in 2019.
Across 559 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Grifols USA, LLC$528
- Sanofi$487
- Covis Pharma GmbH$392
- plus $3K from 20 others
What the payments were for
- Food & beverage$8,64598%
- Education$2142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 85 | $1,733 |
| GSK | 125 | $1,588 |
| Regeneron Healthcare Solutions, Inc. | 60 | $1,064 |
| Grifols USA, LLC | 33 | $528 |
| Sanofi | 28 | $487 |
| Covis Pharma GmbH | 29 | $392 |
| Amgen | 19 | $372 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $326 |
| Genentech USA, Inc. | 19 | $310 |
| CSL Behring | 17 | $305 |
| Teva Pharmaceuticals USA, Inc. | 27 | $265 |
| Optinose US, Inc. | 24 | $235 |
| Boehringer Ingelheim | 14 | $224 |
| Novartis | 12 | $210 |
| Pfizer | 11 | $166 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $143 |
| Kaleo, Inc. | 8 | $123 |
| Lilly USA, LLC | 6 | $102 |
| Biocryst US Sales Co., LLC | 5 | $84 |
| Aimmune Therapeutics, Inc. | 2 | $40 |
| Biocryst Pharmaceuticals, Inc. | 2 | $33 |
| Verona Pharma, Inc. | 2 | $31 |
| Merck | 2 | $31 |
| Ionis Pharmaceuticals, Inc. | 2 | $30 |
| AbbVie | 1 | $21 |
| Shire North American Group Inc | 1 | $16 |
How this compares
$8,859 in reported general payments places this provider in the 75th percentile of 22 allergy providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 25 | $94,830 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 100 | $76,625 |
| TezspireTezepelumab-Ekko | 11 | $49,167 |
| Qvar RedihalerBeclomethasone Dipropionate | 55 | $22,099 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 72 | $14,226 |
| Spiriva RespimatTiotropium Bromide | 23 | $13,525 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $10,262 |
| Arnuity ElliptaFluticasone Furoate | 24 | $10,107 |
| Advair HfaFluticasone Propion/Salmeterol | 29 | $8,853 |
| DuleraMometasone/Formoterol | 14 | $7,854 |
| Pulmicort FlexhalerBudesonide | 15 | $7,089 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $6,226 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $5,005 |
| Budesonide | 12 | $4,278 |
| Azelastine Hcl | 118 | $3,725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,588 | $96,994144 claims |
| AstraZenecaTezspire, Pulmicort Flexhaler, Symbicort | $1,733 | $61,26145 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $265 | $22,09955 claims |
| Boehringer IngelheimSpiriva Respimat | $224 | $13,52523 claims |
| MerckDulera | $31 | $7,85414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 22 allergy providers in Michigan.
Other allergy in Saint Joseph
- Chad MayerFarmington Hills$25K
- Ravinder PolasaniJackson$18K
- Mutee AbdeljaberCaro$12K
- James McClellanTraverse City$11K
- Elena LewisPortage$11K
- Seshagiri DandamudiBattle Creek$7K
- Jasmine AlsukhonNovi$6K
- Claire WardTraverse City$3K
- Lokesh EdaraBattle Creek$3K
- Anna DobrackiBrighton$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.